Avalo Therapeutics (AVTX) Notes Payables (2021 - 2023)

Avalo Therapeutics has reported Notes Payables for 3 years, with the latest figure at $14.1 million in Q2 2023.

• For the quarter ending Q2 2023, Notes Payables changed N/A year-over-year to $14.1 million; the trailing twelve-month figure through Jun 2023 stood at $14.1 million (changed N/A YoY), and the FY2022 full-year result was $5.9 million, changed N/A from the prior year.
• Notes Payables for Q2 2023 stood at $14.1 million, up from $9.3 million in the prior quarter.
• The five-year high for Notes Payables was $33.2 million in Q1 2022, with the low at $2.6 million in Q3 2022.
• Historically, Notes Payables has averaged $16.4 million across 3 years, with a median of $14.1 million in 2023.
• Annual changes were most pronounced in 2022 — Notes Payables sank 92.11% — and 2023, when it slumped 71.99%.
• Avalo Therapeutics' Notes Payables stood at $32.5 million in 2021, then plunged by 81.74% to $5.9 million in 2022, then jumped by 138.03% to $14.1 million in 2023.
• The last three Notes Payables figures came in at $14.1 million (Q2 2023), $9.3 million (Q1 2023), and $5.9 million (Q4 2022), per Business Quant data.